{"id":64146,"date":"2026-04-28T13:16:29","date_gmt":"2026-04-28T05:16:29","guid":{"rendered":"https:\/\/flcube.com\/?p=64146"},"modified":"2026-04-28T13:16:30","modified_gmt":"2026-04-28T05:16:30","slug":"gsks-efimosfermin-receives-dual-regulatory-designations-for-mash-treatment-breakthrough-therapy-and-prime-status-support-phase-iii-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64146","title":{"rendered":"GSK&#8217;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced on April 27, 2026, that <strong>efimosfermin<\/strong>, a once-monthly investigational liver therapy, has received <strong>Breakthrough Therapy Designation<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> and <strong>Priority Medicines (PRIME) Designation<\/strong> from the <strong>European Medicines Agency (EMA)<\/strong> for the treatment of <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Regulatory Agency<\/th><th>Designation<\/th><th>Indication<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. FDA<\/strong><\/td><td>Breakthrough Therapy Designation<\/td><td>MASH treatment<\/td><td>Accelerated development and review pathway<\/td><\/tr><tr><td><strong>European EMA<\/strong><\/td><td>Priority Medicines (PRIME) Designation<\/td><td>MASH treatment<\/td><td>Enhanced scientific support and accelerated assessment<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Metabolic liver disease<\/td><td>F2\/F3 and F4 fibrosis stages<\/td><td>Addresses advanced disease spectrum<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound<\/strong>: Efimosfermin, long-acting variant of <strong>fibroblast growth factor 21 (FGF21)<\/strong><\/li>\n\n\n\n<li><strong>Administration<\/strong>: Once-monthly subcutaneous injection<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Regulates key metabolic pathways to:<\/li>\n\n\n\n<li>Decrease liver fat accumulation<\/li>\n\n\n\n<li>Ameliorate liver inflammation<\/li>\n\n\n\n<li>Reverse liver fibrosis<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: MASH patients with moderate to advanced (F2\/F3) and cirrhotic (F4) fibrosis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-designations\">Clinical Evidence Supporting Designations<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-ii-results-48-week-data\">Phase II Results (48-week data)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>F2\/F3 Patients<\/th><th>Placebo Comparison<\/th><\/tr><\/thead><tbody><tr><td><strong>Fibrosis Improvement<\/strong><\/td><td>Demonstrated significant improvement<\/td><td>Superior to placebo<\/td><\/tr><tr><td><strong>MASH Resolution<\/strong><\/td><td>Achieved resolution in substantial proportion<\/td><td>Statistically significant vs. placebo<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Well-tolerated with mild, transient adverse events<\/td><td>Manageable side effect profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-safety-profile\">Safety Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Common Adverse Events<\/strong>: Nausea, vomiting, and diarrhea<\/li>\n\n\n\n<li><strong>Severity<\/strong>: Mild and transient<\/li>\n\n\n\n<li><strong>Discontinuation Rate<\/strong>: Low due to manageable tolerability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-development-status\">Current Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Program<\/th><th>Status<\/th><th>Patient Population<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>ZENITH-1<\/strong><\/td><td>Phase III ongoing<\/td><td>MASH patients with F2\/F3 fibrosis<\/td><td>Currently enrolling<\/td><\/tr><tr><td><strong>ZENITH-2<\/strong><\/td><td>Phase III ongoing<\/td><td>MASH patients with F2\/F3 fibrosis<\/td><td>Currently enrolling<\/td><\/tr><tr><td><strong>F4 Fibrosis Trials<\/strong><\/td><td>Expected initiation<\/td><td>MASH patients with cirrhotic (F4) fibrosis<\/td><td>Starting 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-significance\">Market Opportunity &amp; Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mash-treatment-landscape\">MASH Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: No approved therapies specifically for MASH with fibrosis<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Millions globally with progressive liver disease<\/li>\n\n\n\n<li><strong>Clinical Endpoints<\/strong>: Fibrosis improvement and MASH resolution represent key regulatory approval criteria<\/li>\n\n\n\n<li><strong>Competitive Position<\/strong>: Dual regulatory designations provide significant development advantages<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-gsk-strategic-implications\">GSK Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Liver Disease Franchise<\/strong>: Expands GSK&#8217;s presence in metabolic and liver diseases<\/li>\n\n\n\n<li><strong>Development Acceleration<\/strong>: Breakthrough and PRIME designations enable faster time-to-market<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: First-in-class monthly dosing regimen offers patient compliance advantages<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Strong Phase II data supports substantial Phase III investment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-advantages\">Regulatory Advantages<\/h2>\n\n\n\n<p>The dual designation represents rare simultaneous recognition from both major regulatory agencies, providing GSK with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enhanced regulatory guidance and support<\/li>\n\n\n\n<li>Potential for rolling BLA\/MAA submissions<\/li>\n\n\n\n<li>Priority review upon filing<\/li>\n\n\n\n<li>Extended market exclusivity opportunities<\/li>\n\n\n\n<li>Streamlined development timelines<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory designations, clinical development, and commercial potential. Actual outcomes may differ due to risks including Phase III trial results, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,278,184,914,80],"class_list":["post-64146","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64146\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64146\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T05:16:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T05:16:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development\",\"datePublished\":\"2026-04-28T05:16:29+00:00\",\"dateModified\":\"2026-04-28T05:16:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64146#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64146\",\"name\":\"GSK's Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T05:16:29+00:00\",\"dateModified\":\"2026-04-28T05:16:30+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64146\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64146#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64146","og_locale":"en_US","og_type":"article","og_title":"GSK's Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development","og_description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","og_url":"https:\/\/flcube.com\/?p=64146","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T05:16:29+00:00","article_modified_time":"2026-04-28T05:16:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64146#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64146"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development","datePublished":"2026-04-28T05:16:29+00:00","dateModified":"2026-04-28T05:16:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64146"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","GlaxoSmithKline","GSK","NYSE: GSK","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64146#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64146","url":"https:\/\/flcube.com\/?p=64146","name":"GSK's Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T05:16:29+00:00","dateModified":"2026-04-28T05:16:30+00:00","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational liver therapy, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64146#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64146"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64146#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment \u2013 Breakthrough Therapy and PRIME Status Support Phase III Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64146"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64146\/revisions"}],"predecessor-version":[{"id":64147,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64146\/revisions\/64147"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}